UCB
Generated by Meeveem AI
"A global biopharmaceutical company creating solutions for severe neurological and autoimmune disease"
About UCB
UCB is a global biopharmaceutical company researching, developing and delivering medicines for severe neurological and autoimmune diseases. Its work focuses on neurology and immunology, including epilepsy, myasthenia gravis, psoriasis, hidradenitis suppurativa and osteoporosis. The company works with patients, carers and healthcare professionals to inform research priorities and the development of treatments.
Founded in 1928 and headquartered in Brussels, UCB operates across nearly 40 countries. It reported 10,117 employees worldwide at the end of 2025, including 883 in the United Kingdom. Its British operations include sites in Slough and Windlesham, linking the group's international medicines business with a substantial UK research and development presence.
Learning and internal mobility
UCB supports ongoing personal development plans and access to learning and mobility platforms. Its 2025 report describes LinkedIn Learning for all interested employees, a shared learning portfolio for transferable skills and an internal opportunity marketplace for career moves. Leadership programmes support managers at different levels.
10117
Team Members
1928
Founded
Pharma
Sector
Hybrid
Work Environment